Pharmaceuticals
Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
* Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated * Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued clinical development * Additional data presented by Brii's licensing part...
2022-10-19 20:00
3701
MedAlliance to be Acquired by Cordis
GENEVA, Oct. 19, 2022 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has announced it has entered into an agreement with Cordis for an acquisition which includes an initial investment of$35M and upfront closing payment of$200M, regulatory achievement milestones of up to $125M ...
2022-10-19 08:00
3279
Rhovac board member resigns due to health reasons
LUND, Sweden, Oct. 18, 2022 /PRNewswire/ -- RhoVac AB (publ) announces today, October 18th 2022, that board member and co-founder Anders Ljungqvist is resigning from the board at his own request due to health reasons. Gunnar Gårdemyr, chairman of the board, comments: "On behalf of the board, I w...
2022-10-18 21:29
2022
Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment
Study evaluates AB-101a for patients with and without concurrent bacterial infection ANNAPOLIS, Md., Oct. 18, 2022 /PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that enrollment in its Phase2a clinical t...
2022-10-18 19:30
2406
CSafe Continues Expansion of Its Temperature-Controlled Shipping Solutions Portfolio with Introduction of Advanced Reusable Pallet Shipper
Loaded with innovation and technology, CSafeAPS provides superior temperature control and the industry's only in-transit thermal capacity indicator MONROE, Ohio, Oct. 18, 2022 /PRNewswire/ -- CSafe, the largest provider of a complete range of active and passive temperature-controlled shipping sol...
2022-10-18 19:00
3827
TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM
* OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast cancer – early results suggest potential to detect carbonic anhydrase IX (CAIX) expression, theranostic potential in this difficult to treat disease. * PERTINENCE Early Phase I feasibility study of ...
2022-10-18 06:43
2315
Kira Pharmaceuticals to Present First-in-Human Clinical Data at American Society for Nephrology Kidney Week 2022
Phase 1 biomarker data confirms proof of mechanism with dose-dependent and potent inhibition of alternative and terminal pathways with KP104 via dual-targeting mechanism Data demonstrated KP104 was safe and well tolerated, and supports further investigation of KP104 in Phase 2 clinical studies ...
2022-10-17 19:00
2848
Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market
* New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare's immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trials * Telix tracers evaluate levels of carbonic anhydrase IX and lactate in tumours to inform and improve ther...
2022-10-17 13:00
2976
Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine
ROCKVILLE, Md. and SUZHOU, China, Oct. 17, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major d...
2022-10-17 08:00
5014
Kira Pharmaceuticals Announces IND Approval from Chinese NMPA for Phase 2 Evaluation of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
CAMBRIDGE, Mass. and SUZHOU, China, Oct. 17, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today that the Chinese National Medical Products Administration (NMPA) has cleared t...
2022-10-17 07:31
2869
Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging
MELBOURNE, Australia, Oct. 17, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an investigational new drug (IND) application to commence...
2022-10-17 07:25
2454
Transcenta to Present Two Scientific Posters at SITC 2022 Annual Meeting
SUZHOU, China, Oct. 14, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it will present ...
2022-10-14 08:00
3481
Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety
* The Digital Therapeutic (DTx) was developed by DTx leader Alex Therapeutics using the proprietary "Alex DTx Platform"[1] in partnership with Vicore Pharma * In the study patients with Idiopathic Pulmonary Fibrosis (IPF) and anxiety were given the DTx * Safety, functionality, and user exper...
2022-10-13 14:39
1895
Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab
BEIJING, SHANGHAI and BOSTON, Oct. 13, 2022 /PRNewswire/ -- Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on clinical study of combination therapy between Jacobio's KRAS G12C inhibitor JAB-21822 and Merck's epidermal growth factor receptor (EGFR) inhibi...
2022-10-13 09:00
3112
RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis
YANTAI, China, Oct. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) for its proprietary novel fusion prote...
2022-10-13 08:00
4362
Dr Ivan Puah, Liposuction Doctor In Singapore, Shares The Secret To Achieving A Good Liposuction Result
Liposuction is more than just what meets the eye. It is a procedure that combines science and art. SINGAPORE, Oct. 12, 2022 /PRNewswire/ -- Liposuction continuously ranks as one of the most preferred fat removal options. Its efficacy, however, does not reflect the intricacies and complexiti...
2022-10-12 11:38
2604
WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody
SHANGHAI, Oct. 11, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem BioPharma, a biotech startup company fromKyoto University, today announced that they have signed a Memorandum of Under...
2022-10-12 09:00
3393
CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy market
CSafe joins BioLife's global partner network of cold chain solution providers using the evo® cold chain management platform MONROE, Ohio and BOTHELL, Wash., Oct. 11, 2022 /PRNewswire/ -- CSafe, one of the largest active and passive temperature-controlled shipping solutions providers for pharmace...
2022-10-11 22:10
5044
Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib
Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency This submission follows the grant of accelerated assessment allowing an expedited review for leniolisib from a standard 210 days to 150 days LEIDEN...
2022-10-11 13:00
2697
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, Oct. 10, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina has approved ...
2022-10-10 20:00
4802
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
[Picked up by 266 media titles]
2026-09-07 13:00
People See One Brand. The Internet May Show Them Hundreds More.
[Picked up by 264 media titles]
2026-09-07 09:00Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00Nuix Expands Generative AI for Legal Review, Debuts AI Chat for Case Data
[Picked up by 262 media titles]
2026-09-07 09:40Most Read
AIA Australia, Long Service Corporation, New Zealand Police and RMBL Investments Named 2026 Appian APJ Innovation Award Winners
2026-09-07 11:28
8012
Sungrow Calls for Scenario-based and integrated systems to Accelerate the Next Phase of the Renewable Energy Transition
2026-09-09 22:26
6808
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
2026-09-07 13:00
6159